Insights

Cutting-Edge Biotech Research Nosopharm leads innovative research in biotechnology, focusing on combating antimicrobial resistance with novel molecules. The company's mission to address unmet medical needs through first-in-class anti-infectives presents significant sales opportunities for pharmaceutical partnerships.

Unique Drug Discovery Platform Nosopharm's bioresource-driven drug discovery platform, leveraging Xenorhabdus and Photorhabdus bacterial genera, offers a distinctive approach that can attract collaborations with companies seeking novel mechanisms of action in antimicrobial therapies.

Strategic Funding & Expansion With recent funding of $1.2M and a revenue range of $0-10M, Nosopharm's financial stability positions it as a potential partner for investors looking to support innovative biotech ventures, signaling growth opportunities and the chance to be part of a successful financial trajectory.

Tech Stack for Efficiency Nosopharm's technology stack, featuring tools such as CookieFirst, Plesk, and UNIX among others, showcases a commitment to efficient operations. Companies offering complementary tech solutions can explore partnerships to enhance Nosopharm's research capabilities further.

Innovative Bio-Tech Ecosystem Being part of the biotechnology ecosystem alongside similar companies like Theranexus and SparingVision, Nosopharm can leverage synergies, industry intelligence, and collaboration opportunities within the sector to drive sales growth, foster innovation, and expand market reach.

Similar companies to Nosopharm

Nosopharm Tech Stack

Nosopharm uses 8 technology products and services including CookieFirst, Plesk, Preact, and more. Explore Nosopharm's tech stack below.

  • CookieFirst
    Cookie Compliance
  • Plesk
    Hosting Panels
  • Preact
    Javascript Libraries
  • Lightbox
    Javascript Libraries
  • UNIX
    Operating Systems
  • reCAPTCHA
    Security
  • OpenSSL
    Web Server Extensions
  • Apache HTTP Server
    Web Servers

Media & News

Nosopharm's Email Address Formats

Nosopharm uses at least 1 format(s):
Nosopharm Email FormatsExamplePercentage
First.Last@nosopharm.comJohn.Doe@nosopharm.com
41%
Last@nosopharm.comDoe@nosopharm.com
12%
F.Last@nosopharm.comJ.Doe@nosopharm.com
6%
First.Last@nosopharm.comJohn.Doe@nosopharm.com
41%

Frequently Asked Questions

Where is Nosopharm's headquarters located?

Minus sign iconPlus sign icon
Nosopharm's main headquarters is located at 21 avenue Georges Pompidou Danica B Lyon, ARA 69003 FR. The company has employees across 1 continents, including Europe.

What is Nosopharm's phone number?

Minus sign iconPlus sign icon
You can contact Nosopharm's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Nosopharm's official website and social media links?

Minus sign iconPlus sign icon
Nosopharm's official website is nosopharm.com and has social profiles on LinkedIn.

How much revenue does Nosopharm generate?

Minus sign iconPlus sign icon
As of March 2024, Nosopharm's annual revenue reached $750K.

What is Nosopharm's SIC code NAICS code?

Minus sign iconPlus sign icon
Nosopharm's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Nosopharm have currently?

Minus sign iconPlus sign icon
As of March 2024, Nosopharm has approximately 7 employees across 1 continents, including Europe. Key team members include Chief Development Officer: S. G.Head Of Non-Clinical Development: E. R.Cso: M. G.. Explore Nosopharm's employee directory with LeadIQ.

What industry does Nosopharm belong to?

Minus sign iconPlus sign icon
Nosopharm operates in the Biotechnology Research industry.

What technology does Nosopharm use?

Minus sign iconPlus sign icon
Nosopharm's tech stack includes CookieFirstPleskPreactLightboxUNIXreCAPTCHAOpenSSLApache HTTP Server.

What is Nosopharm's email format?

Minus sign iconPlus sign icon
Nosopharm's email format typically follows the pattern of . Find more Nosopharm email formats with LeadIQ.

How much funding has Nosopharm raised to date?

Minus sign iconPlus sign icon
As of March 2024, Nosopharm has raised $1.2M in funding. The last funding round occurred on Feb 12, 2018 for $1.2M.

When was Nosopharm founded?

Minus sign iconPlus sign icon
Nosopharm was founded in 2009.
Nosopharm

Nosopharm

Biotechnology ResearchAuvergne-Rhône-Alpes, France2-10 Employees

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR).

The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs.

The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Section iconCompany Overview

Headquarters
21 avenue Georges Pompidou Danica B Lyon, ARA 69003 FR
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
2-10

Section iconMedia & News

Section iconFunding & Financials

  • $1.2M

    Nosopharm has raised a total of $1.2M of funding over 3 rounds. Their latest funding round was raised on Feb 12, 2018 in the amount of $1.2M.

  • $10M

    Nosopharm's revenue is in the range of $10M

Section iconFunding & Financials

  • $1.2M

    Nosopharm has raised a total of $1.2M of funding over 3 rounds. Their latest funding round was raised on Feb 12, 2018 in the amount of $1.2M.

  • $10M

    Nosopharm's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.